Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?

Asthma is one of many chronic airway diseases characterised by inflammation, yet is more uniquely associated with variable airflow obstruction [1]. This heterogeneous pathology affects all age groups and can take different forms, including a type 2 inflammatory phenotype [2].